Robert F. Kennedy Jr., who awaits confirmation as Donald Trump's Health and Human Services secretary, helped organize mass ...

(Reuters) - Robert F. Kennedy Jr. played an instrumental role in organizing mass litigation against drugmaker Merck over its ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Co., Inc. (NYSE:MRK), a global healthcare leader, faces a complex landscape of opportunities and challenges as it navigates the competitive biopharmaceutical industry. This comprehensive analysis ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

We believe investors with a long-term horizon should hold MRK stock, while short-term investors should consider selling it.

Such heightened risk could lead vaccine makers to raise prices or pull a product off the market, said John Grabenstein, a consultant and former Merck vaccine distribution executive who is not ...